株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

人工呼吸器関連肺炎(VAP): パイプライン分析

Ventilator Associated Pneumonia (VAP) - Pipeline Review, H1 2017

発行 Global Markets Direct 商品コード 264097
出版日 ページ情報 英文 133 Pages
即納可能
価格
本日の銀行送金レート: 1USD=110.31円で換算しております。
Back to Top
人工呼吸器関連肺炎(VAP): パイプライン分析 Ventilator Associated Pneumonia (VAP) - Pipeline Review, H1 2017
出版日: 2017年02月28日 ページ情報: 英文 133 Pages
概要

人工呼吸器関連肺炎(VAP)は、気管チューブまたは気管開口による人工呼吸器装着後48時間以降に発症する肺炎で、下気道や肺質への微生物侵入が原因です。最も重要な兆候は熱、低体温、膿性痰、低酸素血です。

当レポートでは、人工呼吸器関連肺炎(VAP)に対する治療薬の開発状況について調査分析し、パイプライン製品の概要、治験の段階別の製品の概要、主要企業プロファイル、薬剤のプロファイル、パイプライン製品の最新動向、最新ニュースとプレスリリースなどについて、体系的な情報を提供しています。

目次

イントロダクション

人工呼吸器関連肺炎(VAP)の概要

治療薬の開発

  • パイプライン製品:概要
  • パイプライン製品:比較分析

開発中の治療薬:企業別

調査中の治療薬:大学/研究機関別

パイプライン製品の概要

  • 後期段階の製品
  • 治験段階の製品
  • 初期段階の製品
  • 開発段階が不明の製品

開発中の製品:企業別

調査中の製品:大学/研究機関別

治療薬の開発に従事している企業

  • Achaogen Inc.
  • Adenium Biotech ApS
  • Aridis Pharmaceuticals LLC
  • AstraZeneca Plc
  • Cardeas Pharma Corp.
  • MedImmune, LLC
  • Meiji Seikaファルマ
  • Merck & Co., Inc.
  • Motif Bio Plc
  • Nabriva Therapeutics AG
  • Savara Inc.
  • Tetraphase Pharmaceuticals Inc.

治療薬の評価

  • 単独療法の製品
  • 併用療法の製品
  • 標的別
  • 作用機序別
  • 投与経路別
  • 分子タイプ別

薬剤のプロファイル

  • (アミカシン + ホスホマイシン)
  • (アビバクタム + セフタジジム)
  • (セフトロザン硫酸塩 + タゾバクタムナトリウム)
  • (シラスタチンナトリウム + イミペネム + レレバクタム)
  • (シュードモナス菌 + 人工呼吸器関連肺炎) ワクチン
  • AA-139
  • Aerucin
  • アルベカシン
  • eravacycline
  • ホスホマイシン・トロメタミン
  • iclaprim mesylate
  • lefamulin acetate
  • MEDI-4893
  • Nu-2
  • Panaecin
  • panobacumab
  • plazomicin sulfate
  • Qn-2251
  • tedizolid phosphate
  • tosatoxumab
  • バンコマイシン塩酸塩

パイプライン製品の最新動向

休止中のプロジェクト

開発が中止された製品

製品開発のマイルストーン

  • 注目情報とプレスリリース

付録

図表

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC8998IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Ventilator Associated Pneumonia (VAP) - Pipeline Review, H1 2017, provides an overview of the Ventilator Associated Pneumonia (VAP) (Infectious Disease) pipeline landscape.

Ventilator-associated pneumonia (VAP) is pneumonia that develops 48 hours or longer after mechanical ventilation is given by means of an endotracheal tube or tracheostomy. Ventilator-associated pneumonia (VAP) results from the invasion of the lower respiratory tract and lung parenchyma by microorganisms. The most important signs are fever, low body temperature, new purulent sputum, and hypoxemia (decreasing amounts of oxygen in the blood).

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Ventilator Associated Pneumonia (VAP) - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Ventilator Associated Pneumonia (VAP) (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Ventilator Associated Pneumonia (VAP) (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Ventilator Associated Pneumonia (VAP) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 7, 7, 5, 11, 1 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.

Ventilator Associated Pneumonia (VAP) (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Ventilator Associated Pneumonia (VAP) (Infectious Disease).
  • The pipeline guide reviews pipeline therapeutics for Ventilator Associated Pneumonia (VAP) (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Ventilator Associated Pneumonia (VAP) (Infectious Disease) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Ventilator Associated Pneumonia (VAP) (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Ventilator Associated Pneumonia (VAP) (Infectious Disease)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Ventilator Associated Pneumonia (VAP) (Infectious Disease).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Ventilator Associated Pneumonia (VAP) (Infectious Disease) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Ventilator Associated Pneumonia (VAP) - Overview
  • Ventilator Associated Pneumonia (VAP) - Therapeutics Development
    • Pipeline Overview
    • Pipeline by Companies
    • Pipeline by Universities/Institutes
    • Products under Development by Companies
    • Products under Development by Universities/Institutes
  • Ventilator Associated Pneumonia (VAP) - Therapeutics Assessment
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Ventilator Associated Pneumonia (VAP) - Companies Involved in Therapeutics Development
    • Achaogen Inc
    • Adenium Biotech ApS
    • Aridis Pharmaceuticals LLC
    • AstraZeneca Plc
    • Bayer AG
    • Cardeas Pharma Corp
    • Destiny Pharma Ltd
    • Dong-A Socio Holdings Co Ltd
    • Lakewood-Amedex Inc
    • MedImmune LLC
    • Meiji Seika Pharma Co Ltd
    • Merck & Co Inc
    • Motif Bio Plc
    • Nabriva Therapeutics AG
    • Polyphor Ltd
    • Shionogi & Co Ltd
    • TGV-Inhalonix Inc
    • The Medicines Company
    • Theravance Biopharma Inc
    • Wockhardt Ltd
    • Zavante Therapeutics Inc
  • Ventilator Associated Pneumonia (VAP) - Drug Profiles
    • (amikacin sulfate + fosfomycin) - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • (avibactam + ceftazidime) - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • (avibactam sodium + aztreonam lysine) - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • (ceftolozane sulfate + tazobactam sodium) - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • (cilastatin sodium + imipenem + relebactam) - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • (meropenem+ vaborbactam) - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • (Pseudomonas + ventilator associated pneumonia) vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • AA-139 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Aerucin - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • amikacin sulfate - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • arbekacin - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • cefepime + zidebactam - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • cefiderocol - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • EBX-004 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • eravacycline - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • exeporfinium chloride - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • fosfomycin tromethamine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • iclaprim mesylate - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • lefamulin acetate - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Mul-1867 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Nu-2 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Nu-3 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Panaecin - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • panobacumab - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • plazomicin sulfate - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • POL-7001 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Qn-2251 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • sodium hypochlorite - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • suvratoxumab - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • tedizolid phosphate - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • telavancin hydrochloride - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • tosatoxumab - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Viritron VDX - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Ventilator Associated Pneumonia (VAP) - Dormant Projects
  • Ventilator Associated Pneumonia (VAP) - Discontinued Products
  • Ventilator Associated Pneumonia (VAP) - Product Development Milestones
    • Featured News & Press Releases
      • Oct 31, 2016: Theravance Biopharma Presents Interim Data from Ongoing Telavancin Observational Use Registry (TOUR) at IDWeek 2016
      • Jun 28, 2016: New antibiotic Zavicefta approved in the European Union for patients with serious bacterial infections
      • May 16, 2016: New Data Analyses From Phase 3 ATTAIN Trials Support VIBATIV(R) (Telavancin) as a Treatment for Staphylococcus Aureus HABP/VABP, Including Cases Caused by MRSA
      • May 11, 2016: Theravance Biopharma to Present New Data Analyses From Phase 3 ATTAIN Trials of VIBATIV (telavancin) in Treatment of HABP/VABP at American Thoracic Society 2016 International Conference
      • Feb 26, 2016: Pendopharm Launches Vibativ In Canada
      • Feb 24, 2016: Aridis Pharmaceuticals Expands Patent Portfolio for Several Fully Human Monoclonal Antibodies Against Infectious Disease Targets
      • Jan 07, 2016: Aridis Pharmaceuticals Reports Positive Phase 1 Clinical Results for Aerucin for Treating Hospital-Acquired and Ventilator-Associated Pneumonia
      • Dec 15, 2015: Iclaprim Clinical Trial Supplies Manufactured
      • Sep 10, 2015: Theravance Biopharma Announces FDA Acceptance of sNDA to Expand VIBATIV Labeling
      • Jul 23, 2015: Theravance Biopharma Announces Health Canada Approval for VIBATIV(telavancin) for Treatment of HAP/VAP Caused by Gram-Positive Bacteria, Including MRSA
      • Jun 30, 2015: Aridis Pharmaceuticals Receives FDA Fast Track Designation for Aerucin for Treating Hospital-Acquired and Ventilator-Associated Pneumonia
      • May 29, 2015: Meiji announces that FDA Grants QIDP and Fast Track Designation to ME1100
      • Feb 10, 2015: Theravance Biopharma Initiates Patient Registry Study for VIBATIV (telavancin)
      • Jul 26, 2013: Meiji Initiates Phase 1 Clinical Trial of Arbekacin Inhalation Solution (ME1100) in the U.S.
      • Jun 21, 2013: Theravance Gets FDA Approval For Vibativ For Treatment Of Hospital-Acquired And Ventilator-Associated Bacterial Pneumonia
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Ventilator Associated Pneumonia (VAP), H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017
  • Number of Products under Development by Universities/Institutes, H1 2017
  • Products under Development by Companies, H1 2017
  • Products under Development by Companies, H1 2017 (Contd..1), H1 2017
  • Products under Development by Universities/Institutes, H1 2017
  • Number of Products by Stage and Target, H1 2017
  • Number of Products by Stage and Mechanism of Action, H1 2017
  • Number of Products by Stage and Route of Administration, H1 2017
  • Number of Products by Stage and Molecule Type, H1 2017
  • Ventilator Associated Pneumonia (VAP) - Pipeline by Achaogen Inc, H1 2017
  • Ventilator Associated Pneumonia (VAP) - Pipeline by Adenium Biotech ApS, H1 2017
  • Ventilator Associated Pneumonia (VAP) - Pipeline by Aridis Pharmaceuticals LLC, H1 2017
  • Ventilator Associated Pneumonia (VAP) - Pipeline by AstraZeneca Plc, H1 2017
  • Ventilator Associated Pneumonia (VAP) - Pipeline by Bayer AG, H1 2017
  • Ventilator Associated Pneumonia (VAP) - Pipeline by Cardeas Pharma Corp, H1 2017
  • Ventilator Associated Pneumonia (VAP) - Pipeline by Destiny Pharma Ltd, H1 2017
  • Ventilator Associated Pneumonia (VAP) - Pipeline by Dong-A Socio Holdings Co Ltd, H1 2017
  • Ventilator Associated Pneumonia (VAP) - Pipeline by Lakewood-Amedex Inc, H1 2017
  • Ventilator Associated Pneumonia (VAP) - Pipeline by MedImmune LLC, H1 2017
  • Ventilator Associated Pneumonia (VAP) - Pipeline by Meiji Seika Pharma Co Ltd, H1 2017
  • Ventilator Associated Pneumonia (VAP) - Pipeline by Merck & Co Inc, H1 2017
  • Ventilator Associated Pneumonia (VAP) - Pipeline by Motif Bio Plc, H1 2017
  • Ventilator Associated Pneumonia (VAP) - Pipeline by Nabriva Therapeutics AG, H1 2017
  • Ventilator Associated Pneumonia (VAP) - Pipeline by Polyphor Ltd, H1 2017
  • Ventilator Associated Pneumonia (VAP) - Pipeline by Shionogi & Co Ltd, H1 2017
  • Ventilator Associated Pneumonia (VAP) - Pipeline by TGV-Inhalonix Inc, H1 2017
  • Ventilator Associated Pneumonia (VAP) - Pipeline by The Medicines Company, H1 2017
  • Ventilator Associated Pneumonia (VAP) - Pipeline by Theravance Biopharma Inc, H1 2017
  • Ventilator Associated Pneumonia (VAP) - Pipeline by Wockhardt Ltd, H1 2017
  • Ventilator Associated Pneumonia (VAP) - Pipeline by Zavante Therapeutics Inc, H1 2017
  • Ventilator Associated Pneumonia (VAP) - Dormant Projects, H1 2017
  • Ventilator Associated Pneumonia (VAP) - Discontinued Products, H1 2017

List of Figures

  • Number of Products under Development for Ventilator Associated Pneumonia (VAP), H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Number of Products by Top 10 Targets, H1 2017
  • Number of Products by Stage and Top 10 Targets, H1 2017
  • Number of Products by Top 10 Mechanism of Actions, H1 2017
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017
  • Number of Products by Routes of Administration, H1 2017
  • Number of Products by Stage and Routes of Administration, H1 2017
  • Number of Products by Molecule Types, H1 2017
  • Number of Products by Stage and Molecule Types, H1 2017
Back to Top